Drug intelligence / Profile preview

YYSW001

Development stage: Preclinical
Lead developer: Monyan
Modality: Small Molecules
Administration: Oral

Overview

YYSW001 is a small molecule, Class 1 chemical drug candidate currently under development by Monyan Pharmaceutical for the treatment of rheumatoid arthritis. As of 2024, the program is in the IND-enabling stage, with clinical trial approval anticipated in 2026. While the specific biological target has not been publicly disclosed, the drug is part of Monyan's pipeline focused on innovative therapies for autoimmune and inflammatory diseases.

Other names: YYSW001YYSW-001YYSW 001

Targets

JAK2 (Janus kinase 2)JAK1 (Janus kinase 1)

Beyond the preview

Go deeper on YYSW001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YYSW001.

Explore the full profile